ChemicalBook > Product Catalog >API >Hormones and the Endocrine System >Erectile Dysfunction Treatment >Darifenacin

Darifenacin

Darifenacin Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Darifenacin
CAS:133099-04-4
Purity:99% Package:100g,500g,1kg,5kg,10kg
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:133099-04-4
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: career henan chemical co
Tel: +86-371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Darifenacin
CAS: 133099-04-4
Purity:99% Package:1kg;7USD
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Email: linda@hubeijusheng.com
Products Intro: Product Name:Darifenacin
CAS:133099-04-4
Purity:0.99 Package:5KG;1KG
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-13650506873
Email: sales@chemdad.com
Products Intro: Product Name:Darifenacin
CAS:133099-04-4
Purity:0.98 Package:1kg,2kg,5kg,10kg,25kg

Lastest Price from Darifenacin manufacturers

  • Darifenacin
  • US $7.00 / kg
  • 2019-07-06
  • CAS: 133099-04-4
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Darifenacin Basic information
Product Name:Darifenacin
Synonyms:CS-773;2-(1-(2-(2,3-Dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetaMide;UK 88525;UK88525;UK-88525;2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-dip;Darifenacin, >=98%;DARIFENACIN
CAS:133099-04-4
MF:C28H30N2O2
MW:426.55
EINECS:
Product Categories:Pharmaceutical material and intermeidates;API
Mol File:133099-04-4.mol
Darifenacin Structure
Darifenacin Chemical Properties
alpha 25D -20.6° (c = 1.0 in methylene chloride)
Boiling point 614.3±55.0 °C(Predicted)
density 1.192±0.06 g/cm3(Predicted)
pkapKa (25°): 9.2
Safety Information
MSDS Information
Darifenacin Usage And Synthesis
DescriptionDarifenacin is a novel muscarinic M3 selective antagonist for the once-daily oral treatment of urinary incontinence and overactive bladder. The majority of overactive bladder symptoms are thought to result from the overactivity of the detrusor muscle, which is primarily mediated by acetylcholine-induced stimulation of muscarinic M3 receptors in the bladder. Consequently, antimuscarinic agents have become the mainstay of overactive bladder treatment. Darifenacin has a higher level of M3 selectivity than the previously marketed antimuscarinic agents. It has Ki values of 16nM for M1, 50 nM for M2, and 1.6 nM for M3 receptors. It is slightly more M3 selective than solifenacin (M1:Ki=25 nM, M2:Ki=126 nM, M3:Ki=10 nM), which was launched in 2004. Darifenacin is significantly more selective than other muscarinics such as tolterodine, oxybutynin, and trospium, which are all essentially equipotent against M1, M2, and M3 receptors. In addition,darifenacin demonstrates greater effect on tissues in which the predominant receptor type is M3 rather than M1 or M2. In vitro darifenacin inhibits carbacholinduced contractions with greater potency in isolated guinea-pig bladder (M3) than in guinea-pig atria (M2) or dog saphenous vein (M1). In animal models, it shows greater selectivity for inhibition of detrusor contraction over salivation or tachycardia.Darifenacin is supplied as a controlled release formulation, and the recommended dosage is 7.5 mg once, daily. Darifenacin is rapidly and completely absorbed from the GI tract after oral administration, with maximum plasma levels achieved after about 7 h. The elimination half-life is approximately 3 h, but because of the controlled release characteristics of the formulation, the drug is suitable for once-daily dosing. Steady-state plasma levels are achieved within 6 days of commencing treatment. Darifenacin exhibits high-protein binding (98%), a volume of distribution of 163 L, and a clearance of 40 L/h. It has low oral bioavailability (15–19%) due to extensive first-pass metabolism by CYP3A4 and CYP2D6, but this can be saturated after multiple administrations. The major circulating metabolites are produced by monohydroxylation and N-dealkylation; however, none contribute significantly to the overall clinical effect of darifenacin. Approximately 58% of the dose is excreted in urine and 44% in feces; only a small percentage (3%) of the excreted dose is unchanged darifenacin.
OriginatorPfizer (US)
UsesTreatment for an overactive bladder.
DefinitionChEBI: 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.
Brand nameEnablex (Novartis);Emselex.
Darifenacin Preparation Products And Raw materials
Tag:Darifenacin(133099-04-4) Related Product Information
Trinexapac-ethyl Ethyl acetate Ethylparaben Thioacetamide Modafinil Phenyl salicylate N,N-Dimethylacetamide darifenacin hydrobromide,DARIFENACIN HYDROBROMIDE 99.0%,Darifenacin hydrobromide (Under R&D),DARIFENACIN HBR,Darifenacin Hydrobromid 2-Cyanoacetamide Solifenacin PHENYL RESIN tadalafi ISOXADIFEN-ETHYL Acetaminophen PHENYL VALERATE Ethanol Piracetam Acetamide